CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Co-Diagnostics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.67+0.01 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $2.87M
- P/E (TTM)
- –
- Dividend yield
- –
Co-Diagnostics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue [Member] | – | – | – | $507.89K | $569.39K | $567.58K | $770.05K | $675.90K | $605.56K | $642.26K | $991.47K | $2.34M | – | – |
| Grant Revenue [Member] | – | – | – | – | – | – | $3.15M | $6.65M | $8.53M | – | $5.82M | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $564.90K | $622.43K | $581.55K | – | – | – | – | $7.04M | $8.88M | $6.39M | $6.48M | $4.19M | 78.3% | – |
| Non-US [Member] | $156.49K | $95.74K | $40.94K | $263.34K | $331.80K | – | $391.84K | – | – | – | – | – | 21.7% | -52.8% |
| Rest of World [Member] | – | – | – | – | $331.80K | $355.49K | $391.84K | $281.29K | $252.62K | $289.50K | $331.86K | $472.92K | – | – |
From the segment and revenue-disaggregation notes of Co-Diagnostics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.